E2F6 and glioblastoma: Immunoblot analyses revealed that E2F6 level was significantly increased in EGFRvIII cells, as compared with vector‐infected GBM cells, and in the cells treated with TMZ (Figure4a,b), suggesting that E2F6 plays a pivotal role in TMZ resistance.